DOCSLIB.ORG

Drug Consumption at Wholesale Prices in 2017 - 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Consumption at Wholesale Prices in 2017 - 2020 Page 1 Drug consumption at wholesale prices in 2017 - 2020 2020 2019 2018 2017 Wholesale Hospit. Wholesale Hospit. Wholesale Hospit. Wholesale Hospit. ATC code Subgroup or chemical substance price/1000 € % price/1000 € % price/1000 € % price/1000 € % A ALIMENTARY TRACT AND METABOLISM 321 590 7 309 580 7 300 278 7 295 060 8 A01 STOMATOLOGICAL PREPARATIONS 2 090 9 1 937 7 1 910 7 2 128 8 A01A STOMATOLOGICAL PREPARATIONS 2 090 9 1 937 7 1 910 7 2 128 8 A01AA Caries prophylactic agents 663 8 611 11 619 12 1 042 11 A01AA01 sodium fluoride 610 8 557 12 498 15 787 14 A01AA03 olaflur 53 1 54 1 50 1 48 1 A01AA51 sodium fluoride, combinations - - - - 71 1 206 1 A01AB Antiinfectives for local oral treatment 1 266 10 1 101 6 1 052 6 944 6 A01AB03 chlorhexidine 930 6 885 7 825 7 706 7 A01AB11 various 335 21 216 0 227 0 238 0 A01AB22 doxycycline - - 0 100 0 100 - - A01AC Corticosteroids for local oral treatment 113 1 153 1 135 1 143 1 A01AC01 triamcinolone 113 1 153 1 135 1 143 1 A01AD Other agents for local oral treatment 49 0 72 0 104 0 - - A01AD02 benzydamine 49 0 72 0 104 0 - - A02 DRUGS FOR ACID RELATED DISORDERS 30 885 4 32 677 4 35 102 5 37 644 7 A02A ANTACIDS 3 681 1 3 565 1 3 357 1 3 385 1 A02AA Magnesium compounds 141 22 151 22 172 22 155 19 A02AA04 magnesium hydroxide 141 22 151 22 172 22 155 19 A02AD Combinations and complexes of aluminium, 3 539 0 3 414 0 3 185 0 3 231 0 calcium and magnesium compounds A02AD01 ordinary salt combinations 3 539 0 3 414 0 3 185 0 3 231 0 A02B DRUGS FOR PEPTIC ULCER AND 27 205 5 29 112 4 31 746 5 34 258 8 GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 551 10 780 7 1 008 7 1 046 7 A02BA02 ranitidine 1 1 396 3 621 3 637 3 A02BA03 famotidine 550 10 384 12 387 14 409 12 A02BB Prostaglandins 80 62 51 73 64 72 52 73 A02BB01 misoprostol 80 62 51 73 64 72 52 73 A02BC Proton pump inhibitors 23 531 4 25 566 4 28 167 5 30 768 8 A02BC01 omeprazole 2 406 3 2 528 3 2 701 3 3 162 2 A02BC02 pantoprazole 8 047 8 9 517 6 11 337 8 13 463 16 Page 2 Drug consumption at wholesale prices in 2017 - 2020 2020 2019 2018 2017 Wholesale Hospit. Wholesale Hospit. Wholesale Hospit. Wholesale Hospit. ATC code Subgroup or chemical substance price/1000 € % price/1000 € % price/1000 € % price/1000 € % A02BC03 lansoprazole 1 205 1 2 077 0 2 655 0 3 174 0 A02BC04 rabeprazole 922 1 852 0 760 0 687 0 A02BC05 esomeprazole 10 950 3 10 592 3 10 714 3 10 282 3 A02BD Combinations for eradication of Helicobacter pylori 218 0 303 0 309 0 322 0 A02BD03 lansoprazole, metronidazole and amoxicillin 23 0 74 0 72 0 74 0 A02BD07 lansoprazole, amoxicillin and clarithromycin 196 0 229 0 238 0 248 0 A02BX Other drugs for peptic ulcer and 2 825 7 2 412 7 2 197 7 2 070 7 gastro-oesophageal reflux disease (GORD) A02BX02 sucralfate 574 21 475 20 411 21 389 19 A02BX13 alginic acid 2 251 3 1 937 3 1 786 4 1 681 4 A03 DRUGS FOR FUNCTIONAL 5 455 46 5 840 51 5 487 45 5 750 48 GASTROINTESTINAL DISORDERS A03A DRUGS FOR FUNCTIONAL 1 895 19 1 872 20 1 772 18 1 808 17 GASTROINTESTINAL DISORDERS A03AB Synthetic anticholinergics, quaternary ammonium 372 87 382 88 307 92 300 91 compounds A03AB02 glycopyrronium bromide 372 87 382 88 307 92 300 91 A03AX Other drugs for functional gastrointestinal disorders 1 523 2 1 490 3 1 464 3 1 508 2 A03AX13 silicones 1 389 3 1 471 3 1 464 3 1 508 2 A03AX15 menthae piperitae aetheroleum 135 0 18 0 - - - - A03B BELLADONNA AND DERIVATIVES, PLAIN 344 93 649 95 543 95 565 86 A03BA Belladonna alkaloids, tertiary amines 285 92 563 94 453 94 427 94 A03BA01 atropine 285 92 563 94 453 94 427 94 A03BB Belladonna alkaloids semisynthetic, quaternary 59 96 86 99 90 99 138 62 ammonium compounds A03BB01 butylscopolamine 59 96 86 99 90 99 138 62 A03C ANTISPASMODICS IN COMBINATION WITH 196 1 222 1 194 1 231 1 PSYCHOLEPTICS A03CA Synthetic anticholinergic agents in combination 196 1 222 1 194 1 231 1 with psycholeptics A03CA02 clidinium and psycholeptics 196 1 222 1 194 1 231 1 A03D ANTISPASMODICS IN COMBINATION WITH 2 599 64 2 710 68 2 577 58 2 685 68 ANALGESICS A03DA Synthetic anticholinergic agents in combination 2 599 64 2 710 68 2 577 58 2 685 68 with analgesics Page 3 Drug consumption at wholesale prices in 2017 - 2020 2020 2019 2018 2017 Wholesale Hospit. Wholesale Hospit. Wholesale Hospit. Wholesale Hospit. ATC code Subgroup or chemical substance price/1000 € % price/1000 € % price/1000 € % price/1000 € % A03DA02 pitofenone and analgesics 2 599 64 2 710 68 2 577 58 2 685 68 A03F PROPULSIVES 421 35 388 37 401 33 461 30 A03FA Propulsives 421 35 388 37 401 33 461 30 A03FA01 metoclopramide 421 35 388 37 401 33 461 30 A04 ANTIEMETICS AND ANTINAUSEANTS 4 860 48 4 198 40 4 126 43 4 576 53 A04A ANTIEMETICS AND ANTINAUSEANTS 4 860 48 4 198 40 4 126 43 4 576 53 A04AA Serotonin (5HT3) antagonists 4 128 48 3 346 38 3 179 42 3 346 58 A04AA01 ondansetron 1 864 65 1 003 41 1 048 45 1 163 51 A04AA02 granisetron 851 41 871 44 888 43 1 146 52 A04AA05 palonosetron 257 99 294 99 313 100 532 100 A04AA55 palonosetron, combinations 1 157 15 1 178 16 930 20 505 45 A04AD Other antiemetics 731 49 852 49 947 44 1 230 37 A04AD01 scopolamine 373 26 300 27 299 27 280 27 A04AD12 aprepitant 359 73 528 62 633 52 946 40 A04AD14 rolapitant - - 24 53 14 66 4 92 A05 BILE AND LIVER THERAPY 1 414 3 2 248 4 2 101 3 2 154 3 A05A BILE THERAPY 1 414 3 2 248 4 2 101 3 2 154 3 A05AA Bile acids and derivatives 1 414 3 2 248 4 2 101 3 2 154 3 A05AA02 ursodeoxycholic acid 1 342 3 2 213 4 2 101 3 2 154 3 A05AA04 obeticholic acid 72 4 35 0 - - - - A06 DRUGS FOR CONSTIPATION 29 145 11 27 151 12 25 595 13 25 606 14 A06A DRUGS FOR CONSTIPATION 29 145 11 27 151 12 25 595 13 25 606 14 A06AB Contact laxatives 3 740 7 3 784 9 3 788 9 3 917 10 A06AB02 bisacodyl 265 2 363 5 385 6 426 7 A06AB06 senna glycosides 52 0 60 0 119 0 128 1 A06AB08 sodium picosulfate 2 819 4 2 688 6 2 653 7 2 736 8 A06AB56 senna glycosides, combinations 163 0 169 0 183 0 201 0 A06AB58 sodium picosulfate, combinations 441 31 505 31 448 30 427 35 A06AC Bulk-forming laxatives 5 859 2 5 297 2 4 883 2 4 770 2 A06AC01 ispaghula (psylla seeds) 5 629 2 5 059 2 4 640 2 4 511 2 A06AC51 ispaghula, combinations 230 1 238 1 244 2 260 2 A06AD Osmotically acting laxatives 16 138 12 14 749 14 13 669 15 13 811 15 A06AD11 lactulose 2 630 9 2 714 10 2 866 11 3 025 12 A06AD15 macrogol 11 751 12 10 211 14 8 940 15 8 322 16 Page 4 Drug consumption at wholesale prices in 2017 - 2020 2020 2019 2018 2017 Wholesale Hospit. Wholesale Hospit. Wholesale Hospit. Wholesale Hospit. ATC code Subgroup or chemical substance price/1000 € % price/1000 € % price/1000 € % price/1000 € % A06AD17 sodium phosphate 41 18 55 16 51 17 74 12 A06AD65 macrogol, combinations 1 716 21 1 768 20 1 813 21 2 391 17 A06AG Enemas 2 419 17 2 518 22 2 636 23 2 699 27 A06AG02 bisacodyl 414 32 422 37 466 40 499 46 A06AG10 docusate sodium, incl. combinations 555 45 592 48 614 51 660 56 A06AG11 laurilsulfate, incl. combinations 1 450 2 1 504 7 1 557 7 1 540 8 A06AH Peripheral opioid receptor antagonists 756 39 623 44 443 52 250 71 A06AH01 methylnaltrexone bromide 133 97 118 95 119 93 145 96 A06AH03 naloxegol 624 26 505 32 324 37 105 38 A06AX Other drugs for constipation 233 11 180 16 175 14 158 10 A06AX04 linaclotide 111 1 66 2 77 2 83 3 A06AX05 prucalopride 122 20 114 24 98 23 75 17 A07 ANTIDIARRHEALS, INTESTINAL 29 004 5 29 697 6 28 909 5 28 669 6 ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS A07A INTESTINAL ANTIINFECTIVES 2 666 34 2 397 40 1 738 45 1 423 57 A07AA Antibiotics 2 666 34 2 397 40 1 738 45 1 423 57 A07AA02 nystatin 679 18 668 22 292 27 21 60 A07AA09 vancomycin 687 53 702 59 670 57 671 57 A07AA11 rifaximin 1 026 20 735 24 545 25 355 26 A07AA12 fidaxomicin 274 73 292 78 231 77 376 87 A07B INTESTINAL ADSORBENTS 668 54 673 53 691 48 726 46 A07BA Charcoal preparations 668 54 673 53 691 48 726 46 A07BA01 medicinal charcoal 668 54 673 53 691 48 726 46 A07C ELECTROLYTES WITH CARBOHYDRATES 138 5 228 5 269 6 272 5 A07CA Oral rehydration salt formulations 138 5 228 5 269 6 272 5 A07D ANTIPROPULSIVES 3 788 1 4 426 1 4 290 1 4 198 1 A07DA Antipropulsives 3 788 1 4 426 1 4 290 1 4 198 1 A07DA03 loperamide 2 962 1 3 407 1 3 221 1 3 246 1 A07DA06 eluxadoline - - 0 0 19 1 13 2 A07DA53 loperamide, combinations 825 0 1 019 0 1 050 0 938 0 A07E INTESTINAL ANTIINFLAMMATORY AGENTS 18 973 1 17 949 1 17 127 1 16 588 1 A07EA Corticosteroids acting locally 1 976 3 1 834 2 1 668 3 1 593 3 A07EA02 hydrocortisone - - - - 0 0 102 3 A07EA06 budesonide 1 976 3 1 834 2 1 667 3 1 491 3 Page 5 Drug consumption at wholesale prices in 2017 - 2020 2020 2019 2018 2017 Wholesale Hospit.
Load more

Recommended publications
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • Injectable PLGA Adefovir Microspheres; the Way for Long Term Therapy of T Chronic Hepatitis-B ⁎ Margrit M
    European Journal of Pharmaceutical Sciences 118 (2018) 24–31 Contents lists available at ScienceDirect European Journal of Pharmaceutical Sciences journal homepage: www.elsevier.com/locate/ejps Injectable PLGA Adefovir microspheres; the way for long term therapy of T chronic hepatitis-B ⁎ Margrit M. Ayouba, , Neveen G. Elantounyb, Hanan M. El-Nahasa, Fakhr El-Din S. Ghazya a Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Zagazig University, Zagazig, Egypt b Department of Internal Medicine, Faculty of Medicine, Zagazig University, Zagazig, Egypt ARTICLE INFO ABSTRACT Keywords: For patient convenience, sustained release Adefovir Poly-d,l-lactic-co-glycolic acid (PLGA) microspheres were Adefovir formulated to relieve the daily use of the drug which is a problem for patients treated from chronic hepatitis-B. Biodegradable microspheres PLGA microspheres were prepared and characterized by entrapment efficiency, particle size distribution and Poly-lactic-co-glycolic acid scanning electron microscopy (SEM). In-vitro release and in-vivo studies were carried out. Factors such as drug: Entrapment efficiency polymer ratio, polymer viscosity and polymer lactide content were found to be important variables for the preparation of PLGA Adefovir microspheres. Fourier transform infrared (FTIR) analysis and differential scanning calorimetry (DSC) were performed to determine any drug-polymer interactions. One way analysis of variance (ANOVA) was employed to analyze the pharmacokinetic parameters after intramuscular injection of the pure drug and the selected PLGA microspheres into rats. FTIR and DSC revealed a significant interaction between the drug and the polymer. Reports of SEM before and after 1 and 24 h release showed that the microspheres had nonporous smooth surface even after 24 h release.
    [Show full text]
  • Hepsera, INN- Defovir Dipivoxil
    SCIENTIFIC DISCUSSION This module reflects the initial scientific discussion for the approval of Hepsera. For information on changes after approvalplease refer to module 8B 1. Chemical, pharmaceutical and biological aspects Composition Hepsera is presented as an immediate release tablet containing 10 mg of adefovir dipivoxil, as active substance. The other ingredients in this formulation are commonly used in tablets Hepsera is supplied in high-density polyethylene bottle (HDPE), with silica gel desiccant canisters or sachets, and polyester fiber packing material. The closure system consists of a child-resistant polypropylene screw cap lined with an induction activated aluminium foil liner. Active substance Adefovir dipivoxil is an ester prodrug of the nucleotide analogue, adefovir. A structural modification of the parent drug has been carried out in order to increase the lipophilicity and to enhance the oral bioavailability of adefovir. The active substance is a white to off-white crystalline powder. It is soluble in ethanol, sparingly soluble in 0.1N HCl and very slightly soluble in water adjusted to pH 7.2 but relatively highly soluble at physiological pH. The active substance does not contain any chiral center and does not exhibit any optical isomerism. In laboratory studies the anhydrate crystal form has been observed to convert gradually into a dihydrate crystal form when adefovir dipivoxil was exposed to high humidity conditions (75% R.H., 25ºC) over an approximately one-month period. However, the only crystal form produced during the active substance synthesis and utilised in non-clinical and clinical studies has been the anhydrous crystal form. Adefovir dipivoxil undergoes also hydrolysis in aqueous solution and to a smaller degree in the solid state after exposure to humidity and heat for extended periods.
    [Show full text]
  • COVID-19) Pandemic on National Antimicrobial Consumption in Jordan
    antibiotics Article An Assessment of the Impact of Coronavirus Disease (COVID-19) Pandemic on National Antimicrobial Consumption in Jordan Sayer Al-Azzam 1, Nizar Mahmoud Mhaidat 1, Hayaa A. Banat 2, Mohammad Alfaour 2, Dana Samih Ahmad 2, Arno Muller 3, Adi Al-Nuseirat 4 , Elizabeth A. Lattyak 5, Barbara R. Conway 6,7 and Mamoon A. Aldeyab 6,* 1 Clinical Pharmacy Department, Jordan University of Science and Technology, Irbid 22110, Jordan; [email protected] (S.A.-A.); [email protected] (N.M.M.) 2 Jordan Food and Drug Administration (JFDA), Amman 11181, Jordan; [email protected] (H.A.B.); [email protected] (M.A.); [email protected] (D.S.A.) 3 Antimicrobial Resistance Division, World Health Organization, Avenue Appia 20, 1211 Geneva, Switzerland; [email protected] 4 World Health Organization Regional Office for the Eastern Mediterranean, Cairo 11371, Egypt; [email protected] 5 Scientific Computing Associates Corp., River Forest, IL 60305, USA; [email protected] 6 Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield HD1 3DH, UK; [email protected] 7 Institute of Skin Integrity and Infection Prevention, University of Huddersfield, Huddersfield HD1 3DH, UK * Correspondence: [email protected] Citation: Al-Azzam, S.; Mhaidat, N.M.; Banat, H.A.; Alfaour, M.; Abstract: Coronavirus disease 2019 (COVID-19) has overlapping clinical characteristics with bacterial Ahmad, D.S.; Muller, A.; Al-Nuseirat, respiratory tract infection, leading to the prescription of potentially unnecessary antibiotics. This A.; Lattyak, E.A.; Conway, B.R.; study aimed at measuring changes and patterns of national antimicrobial use for one year preceding Aldeyab, M.A.
    [Show full text]
  • New Insights Into the Effect of Amorolfine Nail Lacquer
    Review article New insights into the effect of amorolfine nail lacquer C. Flagothier, C. Pie´ rard-Franchimont and G. E. Pie´ rard Department of Dermatopathology, University Hospital of Lie`ge, Lie`ge, Belgium Summary Despite improvements in antifungal strategies, the outcome of treating onychomycoses often remains uncertain. Several factors account for treatment failure, of which the pharmacokinetics and pharmacodynamics of the antifungal are of importance. The taxonomic nature and ungual location of the fungus cannot be neglected, besides the type of nail and its growth rate. In addition, the biological cycle of the fungus and the metabolic activity of the pathogen likely play a marked influence in drug response. The presence of natural antimicrobial peptides in the nail is also probably a key feature controlling the cure rates. There are many outstanding publications that cover the full spectrum of the field. The purpose of this review is to put in perspective some facets of activity of the topical treatment using amorolfine nail laquer. The antifungal activity of the drug is likely less pronounced in onychomycosis than that expected from conventional in vitro studies. However, the nail laquer formulation should reduce the propensity to form antifungal-resistant spores and limit the risk of reinfection. Key words: amorolfine, antifungal, fungus, onychomycosis, spore. Topical treatments are often considered to be less Introduction efficacious than current oral treatments. However, some During the last 2 decades, the efficacy of treating topical formulations may provide effects that cannot be onychomycoses has been considerably improved by achieved by other treatments. In discussing the treat- the introduction of new generations of potent antifun- ment of onychomycosis, it should not be forgotten that gals.
    [Show full text]
  • The Impact of a Changed Legislation on Reporting of Adverse Drug Reactions in Sweden, with Focus on Nurses Reporting
    The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses reporting Sofia A. Karlsson, Ingela Jacobsson, Marit Danell Boman, Katja M. Hakkarainen, Henrik Lövborg, Staffan Hägg and Anna K Jönsson Linköping University Post Print N.B.: When citing this work, cite the original article. The original publication is available at www.springerlink.com: Sofia A. Karlsson, Ingela Jacobsson, Marit Danell Boman, Katja M. Hakkarainen, Henrik Lövborg, Staffan Hägg and Anna K Jönsson, The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses reporting, 2015, European Journal of Clinical Pharmacology, (71), 5, 631-636. http://dx.doi.org/10.1007/s00228-015-1839-6 Copyright: Springer Verlag (Germany) http://www.springerlink.com/?MUD=MP Postprint available at: Linköping University Electronic Press http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-118037 The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses’ reporting Sofia A Karlsson1, Ingela Jacobsson2, Marit Danell Boman3, Katja M Hakkarainen4,5, Henrik Lövborg2, Staffan Hägg2,5, Anna K Jönsson2 Affiliations: 1. Department of Public Health and Community Medicine, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden 2. Department of Clinical Pharmacology and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden 3. Division of Clinical Pharmacology, University Hospital of Umeå, Umeå, Sweden 4. Nordic School of
    [Show full text]
  • The Management of Common Skin Conditions in General Practice
    Management of Common Skin Conditions In General Practice including the “red rash made easy” © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care University of Auckland, Tamaki Campus Reviewed by Hon A/Prof Amanda Oakley - 2019 http://www.dermnetnz.org Management of Common Skin Conditions In General Practice Contents Page Derm Map 3 Classic location: infants & children 4 Classic location: adults 5 Dermatology terminology 6 Common red rashes 7 Other common skin conditions 12 Common viral infections 14 Common bacterial infections 16 Common fungal infections 17 Arthropods 19 Eczema/dermatitis 20 Benign skin lesions 23 Skin cancers 26 Emergency dermatology 28 Clinical diagnosis of melanoma 31 Principles of diagnosis and treatment 32 Principles of treatment of eczema 33 Treatment sequence for psoriasis 34 Topical corticosteroids 35 Combination topical steroid + antimicrobial 36 Safety with topical corticosteroids 36 Emollients 37 Antipruritics 38 For further information, refer to: http://www.dermnetnz.org And http://www.derm-master.com 2 © Arroll, Fishman & Oakley, Department of General Practice and Primary Health Care, University of Auckland, Tamaki Campus. Management of Common Skin Conditions In General Practice DERM MAP Start Is the patient sick ? Yes Rash could be an infection or a drug eruption? No Insect Bites – Crop of grouped papules with a central blister or scab. Is the patient in pain or the rash Yes Infection: cellulitis / erysipelas, impetigo, boil is swelling, oozing or crusting? / folliculitis, herpes simplex / zoster. Urticaria – Smooth skin surface with weals that evolve in minutes to hours. No Is the rash in a classic location? Yes See our classic location chart .
    [Show full text]
  • Assessing the Availability, Service Quality, and Price of Essential Medicines In
    Assessing the Availability, Service Quality, and Price of Essential Medicines in Private Pharmacies in Afghanistan Norio Kasahara A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2015 Reading Committee: Louis P. Garrison, Jr., Chair Joseph B. Babigumira Andy Stergachis Program Authorized to Offer Degree: Pharmaceutical Outcomes Research and Policy ©Copyright 2015 Norio Kasahara ii Table of Contents Abstract ................................................................................................................................................................................... ................................................................................................ ................................................................................................ .................................................................................. ............... vvv Acknowledgements ................................................................................................................................................................................... ................................................................................................ ................................................................................. ............ viiviivii Summary ................................................................................................................................................................................... ...............................................................................................
    [Show full text]
  • Teriparatide Injection I.P. (R-DNA Origin) Interactions Were Noted
    PA011FSRI04 For more information, visit us at www.lillyindia.co.in Interactions with other medicinal products and other forms of interaction Forteo® has been evaluated in pharmacodynamic interaction studies with hydrochlorothiazide. No clinically significant Teriparatide Injection I.P. (r-DNA origin) interactions were noted. ® Co-administration of raloxifene or hormone replacement therapy with Forteo® did not alter the effects of Forteo® on Forteo serum or urine calcium or on clinical adverse events. (600mcg/2.4mL, Solution for injection in a pre-filled pen) In a study of 15 healthy subjects administered digoxin daily to steady state, a single Forteo® dose did not alter the cardiac effect of digoxin. However, sporadic case reports have suggested that hypercalcaemia may predispose patients to digitalis toxicity. Because Forteo® transiently increases serum calcium, Forteo® should be used with caution in patients taking digitalis NAME OF THE MEDICINAL PRODUCT Fertility, pregnancy and lactation Fertility Forteo® 600mcg/2.4mL, solution for injection, in pre-filled pen. Studies in rabbits have shown reproductive toxicity (see section Preclinical safety data). The effect of teriparatide on human foetal development has not been studied. The potential risk for humans is unknown. QUALITATIVE AND QUANTITATIVE COMPOSITION Pregnancy Each mL of Teriparatide Injection I.P. contains: 250 mcg Teriparatide I.P. (r-DNA origin) as active ingredient, Forteo® is contraindicated for use during pregnancy (see section Contraindications) 0.41 mg Glacial Acetic Acid I.P. as buffering agent, 0.10 mg Sodium Acetate (Anhydrous) I.P. as buffering agent, Breast –Feeding 45.4 mg Mannitol I.P. as tonicity modifier, 3.0 mg Metacresol Ph.
    [Show full text]
  • Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020
    First independent framework for assessing pharmaceutical company action Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020 ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report.1 FUNDERS The Antimicrobial Resistance Benchmark research programme is made possible with financial support from UK AID and the Dutch Ministry of Health, Welfare and Sport. Expert Review Committee Research Team Reviewers Hans Hogerzeil - Chair Gabrielle Breugelmans Christine Årdal Gregory Frank Fatema Rafiqi Karen Gallant Nina Grundmann Adrián Alonso Ruiz Hans Hogerzeil Magdalena Kettis Ruth Baron Hitesh Hurkchand Joakim Larsson Dulce Calçada Joakim Larsson Marc Mendelson Moska Hellamand Marc Mendelson Margareth Ndomondo-Sigonda Kevin Outterson Katarina Nedog Sarah Paulin (Observer) Editorial Team Andrew Singer Anna Massey Deirdre Cogan ACCESS TO MEDICINE FOUNDATION Rachel Jones The Access to Medicine Foundation is an independent Emma Ross non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income Additional contributors countries by stimulating and guiding the pharmaceutical Thomas Collin-Lefebvre industry to play a greater role in improving access to Alex Kong medicine. Nestor Papanikolaou Address Contact Naritaweg 227-A For more information about this publication, please contact 1043 CB, Amsterdam Jayasree K. Iyer, Executive Director The Netherlands [email protected] +31 (0) 20 215 35 35 www.amrbenchmark.org 1 This acknowledgement is not intended to imply that the individuals and institutions referred to above endorse About the cover: Young woman from the Antimicrobial Resistance Benchmark methodology, Brazil, where 40%-60% of infections are analyses or results.
    [Show full text]
  • Oral Anticoagulants
    4/26/2018 Disclosure • Kelsey Gander, PharmD, BCACP Direct Oral Anticoagulants: – Declares no financial relationships pertinent to this session When to Use and How to Choose – Declares off-label use of medication will not be discussed during this presentation. Kelsey Gander, PharmD, BCACP Minnesota Academy of Physician Assistants Conference May 11th, 2018 Abbreviations Objectives • DOAC= direct oral anticoagulant 1) Compare and contrast the efficacy and safety • VTE= venous thromboembolism • DVT= deep vein thrombosis of direct oral anticoagulants (DOACs) to • PE= pulmonary embolism warfarin • A-fib, AF= atrial fibrillation 2) Identify which anticoagulant would be most • ESRD= end stage renal disease appropriate for a given patient • ACC= American College of Cardiology • AHA= American Heart Association 3) Recognize when it would not be appropriate • HRS= Heart Rhythm Society to use a DOAC • BID= twice daily Appropriate Abbreviations Patient Case JJ is a 66 y/o male who was hospitalized for pulmonary • NOAC embolism and initiated on anticoagulant therapy one week – Novel Oral Anticoagulant ago. – Chief complaint: – Non-Vitamin K Oral Anticoagulant • Presents to clinic today for INR check, post-hospital discharge follow- up • TSOAC – Past medical history: • Hypertension, hyperlipidemia, osteoarthritis, erectile dysfunction, – Target Specific Oral Anticoagulant BPH, type 2 diabetes, peripheral artery disease – Home medications • DOAC • Acetaminophen 650mg po every 6 hours PRN – Direct Oral Anticoagulant • Diazepam 5mg po at bedtime PRN anxiety
    [Show full text]
  • Orphan Drugs Used for Treatment in Pediatric Patients in the Slovak Republic
    DOI 10.2478/v10219-012-0001-0 ACTA FACULTATIS PHARMACEUTICAE UNIVERSITATIS COMENIANAE Supplementum VI 2012 ORPHAN DRUGS USED FOR TREATMENT IN PEDIATRIC PATIENTS IN THE SLOVAK REPUBLIC 1Foltánová, T. – 2Konečný, M. – 3Hlavatá, A. –.4Štepánková, K. 5Cisárik, F. 1Comenius University in Bratislava, Faculty of Pharmacy, Department of Pharmacology and Toxicology 2Department of Clinical Genetics, St. Elizabeth Cancer Institute, Bratislava 32nd Department of Pediatrics, UniversityChildren'sHospital, Bratislava 4Slovak Cystic Fibrosis Association, Košice 5Department of Medical Genetics, Faculty Hospital, Žilina Due to the enormous success of scientific research in the field of paediatric medicine many once fatal children’s diseases can now be cured. Great progress has also been achieved in the rehabilitation of disabilities. However, there is still a big group of diseases defined as rare, treatment of which has been traditionally neglected by the drug companies mainly due to unprofitability. Since 2000 the treatment of rare diseases has been supported at the European level and in 2007 paediatric legislation was introduced. Both decisions together support treatment of rare diseases in children. In this paper, we shortly characterise the possibilities of rare diseases treatment in children in the Slovak republic and bring the list of orphan medicine products (OMPs) with defined dosing in paediatrics, which were launched in the Slovak market. We also bring a list of OMPs with defined dosing in children, which are not available in the national market. This incentive may help in further formation of the national plan for treating rare diseases as well as improvement in treatment options and availability of rare disease treatment in children in Slovakia.
    [Show full text]